Sign In
Buy RHHBY
$51.57
+2.51 (+5.12%)
At Close: Jun 04, 2026
FDA Ok's Roche's Companion Diagnostic For Pfizer's Lorbrena In Lung Cancer
07:22am, Tuesday, 09'th Mar 2021
The FDA has approved Roche Holdings AG's (OTCMKT: RHHBY) Ventana ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer patients eligible for treatment w
Roche (RHHBY) Withdraws Bladder Cancer Indication for Tecentriq
04:56pm, Monday, 08'th Mar 2021
Roche (RHHBY) voluntarily withdraws the bladder cancer indication of Tecentriq in the United States.
Roche Walks Away From Regular FDA Nod For Tecentriq In Pretreated Bladder Cancer
07:01am, Monday, 08'th Mar 2021
Roche Holding AG (OTCMKT: RHHBF) has joined AstraZeneca Plc (NASDAQ: AZN) in withdrawing cancer immunotherapies from the U.S. for bladder cancer that has already been treated with platinum-based c
Genentech Provides Update on Tecentriq U.S. Indication in Prior-Platinum Treated Metastatic Bladder Cancer
01:00am, Monday, 08'th Mar 2021
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the company is voluntarily withdrawing the U.S. indication for T
Roche's Tocilizumab Injection Wins FDA Approval For Lung Disease
08:00am, Friday, 05'th Mar 2021
The FDA has approved Roche Holdings AG's (OTCQX: RHHBY) Actemra/RoActemra (tocilizumab) for slowing the rate of decline in pulmonary function in adult patients with systemic sclerosis-associated i
Basel, 05 March 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) approved Actemra®/RoActemra® (tocilizumab) subcutaneous injection for slowi
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the U.S. Food and Drug Administration (FDA) approved Actemra® (
Roche SARS-CoV-2 Rapid Antigen Test receives special approval for at-home patient self-testing using nasal swabs in Germany
12:30pm, Friday, 26'th Feb 2021
Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced it has been granted special approval by the German Federal Institute for Drugs and Medical Devices (BfArM) to offer the SAR
EMA issues advice on casirivimab and imdevimab antibody cocktail for the treatment of mild-to-moderate COVID-19
07:12am, Friday, 26'th Feb 2021
Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) confirmed today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a scientific op
Basel, 26 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval
Wide-Moat Stocks On Sale - The March 2021 Heat Map
09:27pm, Thursday, 25'th Feb 2021
Our three-step process focuses on wide-moat stocks (as per Morningstar's rating).
Weill Neurohub joins Genentech and Roche in accelerating neuroscience research
03:25pm, Thursday, 25'th Feb 2021
Weill Neurohub is partnering with Genentech and Roche to accelerate research in neuroscience. Former Citigroup chairman and CEO Sandy Weill, Genentech CEO Alexander Hardy and CNBC's Meg Tirrell join '
Roche Reports Positive Evrysdi Data From Dose-Finding Part Of Spinal Muscular Atrophy Trial
01:46pm, Thursday, 25'th Feb 2021
Roche Holding AG (OTCMKTS: RHHBY) has reported positive data from the dose-finding Part 1 FIREFISH Phase 2/3 study of Evrysdi (risdiplam) in infants with symptomatic Type 1 spinal muscular atroph
Weill Neurohub Joins Forces With Genentech and Roche to Advance Neuroscience Research
10:06am, Thursday, 25'th Feb 2021
SAN FRANCISCO--(BUSINESS WIRE)--UCSF, UC Berkeley announce partnership with Genentech to speed development of therapeutics for brain diseases and CNS disorders such as Alzheimer's.
Basel, 25 February 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the New England Journal of Medicine has published Evrysdi™ (risdiplam) data from the dose finding Part 1 of the pivo
